Physiomics (PYC)

 

PYC Share PerformanceMore

52 week high3.0000 26/09/16
52 week low0.9340 17/07/17
52 week change -1.5750 (-57.27%)
4 week volume7,075,420 29/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Physiomics seals new contracts

Physiomics signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating...

Two New Pre-Clinical Contracts

RNS Number: 4987M Physiomics PLC 31 July 2017 Physiomics plc ("Physiomics") or ("the Company") Two new pre-clinical contracts Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a n...

Physiomics to Attend PAGE 2017

RNS Number: 1956H Physiomics PLC 06 June 2017 Physiomics Plc ("Physiomics" or "the Company") Physiomics to attend PAGE 2017 Oxford, UK, 6 th June 2017: Physiomics is pleased to announce that it will attend the Population Approach Group Europe (PAGE) Annual Conference taking place in Budapest, Hungary 7-9 June. PAGE is Europe's premier conference ...

Update: Two Further Extension Projects

RNS Number: 0270G Physiomics PLC 24 May 2017 Physiomics plc ("Physiomics") or ("the Company") Update: two further extension projects to advance oncology candidate with global pharma company Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been contracted for two further extensions to a Virt...

Physiomics to Present at BioTrinity 2017

RNS Number: 2352E Physiomics PLC 05 May 2017 Physiomics Plc ("Physiomics" or "the Company") Physiomics to Present at BioTrinity 2017 Oxford, UK, 5 th May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe's leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London W...

Physiomics' losses rise

Physiomics has reported an operating loss of 263,509 for the six month period ended 31 December, compared to a restated lo...

Interim Results Statement

RNS Number: 4688A Physiomics PLC 24 March 2017 Physiomics Plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2016 Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2...

Physiomics makes good progress on strategic objectives

Physiomics anticipates that in H1 of its current financial year revenues will be broadly in line with the comparable period...

Fundamental DataMore

EPS-0.01
Dividend yield0 %

Equity Research (PYC)

Physiomics plc
24/03/2017
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients...
Physiomics plc
17/01/2017
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives...
Physiomics plc
01/11/2016
Following the decision not to proceed with the acquisition of oncology therapeutics Company BioMoti, Physiomics is now 100% focused on growing the revenues and creating a path to profitability in the...

Latest discussion posts More

Users' HoldingsMore

Users who hold Physiomics also hold..
SAREUM21%
SOLO OIL19%
RANGE RES.18%
LLOYDS GRP.17%
NOSTRA TERRA16%

Codes & Symbols

ISINGB00BDR6W943
SymbolsPYC, LSE:PYC, PYC.L, PYC:LN, LON:PYC, XLON:PYC